Tuesday, May 5-Thursday, May 7
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
February 27, 2026
February 27, 2026
Posts
Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by @kencardonaMD, aims to find out. Learn more: https://bit.ly/EA7211 #leiomyosarcoma #liposarcoma
Why does #BreastCancer come back after treatment? The EA1241 #ClinicalTrial, led by @jsparano, aims to find out by evaluating tissue samples from patients who previously enrolled in TAILORx & RxPONDER. More: https://bit.ly/EA1241 cc: @KalinskyKevin, @RimapatelMD
Congress...united around the message that NIH funding must be increased, not cut, and must remain a national priority. @AACR_CEO Margaret Foti leads the #AACR26 delegates in thanking Congress for rejecting the Administration's proposal to cut NIH and NCI funding by 40 percent.
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
33
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
